Vendor dossier · Qingdao
Qingdao Saber Technology Pharmaceutical
A Qingdao pharmaceutical trader whose documentation improved sharply after a public disagreement with a testing service.
Journal grade · ranked 6 of 20
519 reader reports
on the record
In late 2024 a purity result published by an independent testing service contradicted a QST certificate by more than three percentage points. The company disputed it publicly, lost the argument on the chromatogram, and then — unusually — changed its release process rather than its story. The certificates issued since are materially better.
Storefront The company sells directly at qingdaosabertechnology.com. Visit QST → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Seven independent purity determinations, mean 97.2%, range 95.4–98.6%. The 95.4% figure is from March 2025 and is the lowest in this dossier outside QSC. Five determinations since June 2025 have all been above 97.5%, which is consistent with the process change the company describes.
What changed, on the company's own account: purity is now determined on every lot rather than every campaign, and a second analyst signs the integration. We cannot verify either claim directly. We can verify that the certificates now carry two signatures and a lot-specific date, and that they did not before.
Catalogue breadth remains the issue. QST lists considerably more than it plausibly makes, and it does resell. Asked which items are in-house, we received a partial list — the first partial list any vendor in this directory has given us, and to be fair, more than most would.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Seven independent purity determinations, mean 97.2% (range 95.4–98.6%); five since June 2025 all above 97.5%.
- Certificates now carry two signatures and a lot-specific determination date; earlier certificates carried neither.
- A partial written list of which catalogue items are synthesised in-house.
- 2017 incorporation in Qingdao, per registry records.
What we could not verify
- That purity is now determined per lot rather than per campaign — claimed, not evidenced.
- The 95.4% March 2025 result, for which no root-cause account has been published.
- Which of the resold items come from which suppliers.
- Sterility and endotoxin. Not offered.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-04 | Medutest | BPC-157 5 mg | 98.9% | 98.4% | 78% |
| 2026-03 | Medutest | Cagrilintide 2 mg | 98.6% | 97.6% | 82% |
| 2025-06 | Janoshik | Tirzepatide 15 mg | 98.9% | 97.5% | not tested |
| 2025-03 | VendorInvestigate | Retatrutide 20 mg | 98.5% | 98.4% | not tested |
| 2024-06 | VendorInvestigate | Retatrutide 5 mg | 98.3% | 96.9% | not tested |
| 2024-04 | PeptideMeter | Retatrutide 20 mg | 99.6% | 99.0% | not tested |
| 2024-03 | Janoshik | Liraglutide 15 mg | 98.1% | 96.9% | not tested |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and the outcome, without editorialising. 2 of 8 logged requests received a full answer within the period.
| Date | Request | Outcome |
|---|---|---|
| 2026-06 | Requested the reference-standard lot number | Acknowledged; no substantive reply |
| 2026-03 | Asked which catalogue items are synthesised in-house | Acknowledged; no substantive reply |
| 2025-10 | Asked whether sterility or endotoxin testing is performed | Acknowledged; no substantive reply |
| 2025-09 | Requested comment on an independent purity determination below the stated figure | Answered with a restatement of published quality claims |
| 2024-10 | Requested the analytical method behind the stated purity figure | Answered in full within 10 working days |
| 2024-08 | Asked for the name of the synthesis facility | Offered a video call in place of a written answer; declined |
| 2024-06 | Requested a batch record for a specific lot | Answered in full within 2 working days |
| 2024-05 | Asked whether corrected certificates are reissued to earlier purchasers | Answered in part; the specific question was not addressed |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
Lot code on the vial matched the lot code on the certificate exactly. Sounds basic; it is the single best predictor of everything else.
Held locally in the United States, so the mazdutide 5 mg arrived on day 5 without an import step.
4 lots logged now, purity 98.1 to 98.2%. A band that tight is worth more to me than one spectacular number.
No customs paperwork, no import wait — it came from their stock in the United Kingdom and arrived day 3.
5 orders in eighteen months, no substitutions, no reformulations, everything in stock when the site said it was. Boring is the highest compliment I have.
They report purity by RP-HPLC with the wavelength stated and peptide content separately. Two different numbers, correctly separated.
Vials wrapped individually, foam cut to fit, nothing loose in the box. Packing that has clearly been thought about.
Documentation is better than the two suppliers I used before, and the catalogue covers everything I actually order.
Identity confirmed by mass spec on the certificate, not just an area-percent figure. Both questions answered on one page.
One of the few places that will quote CJC-1295 2 mg at all, and the synthesis came back clean on an independent check.
Domestic dispatch from their stock in Australia. Straightforward, day 4, exactly as quoted.
Custom synthesis quote came back with a realistic timeline and they beat it. Purity on delivery matched the signed spec.
Every certificate I have from them is lot-specific. Not one batch-level document in 7 orders.
Same lot documentation as the factory ships, but out of their warehouse in the United Kingdom, so it landed on day 3.
Regional stock makes the difference — dispatched within Australia, day 4, cold pack still hard on arrival.
Quoted 5 days, arrived in 5. Tracking updated at every hop from dispatch to door.
Dispatched from their warehouse in Germany rather than from the factory, so the MOTS-c 10 mg was with me on day 2.
Submitted the GHK-Cu 50 mg to Medutest blind, without telling them the source. 99.6% against a stated 99.5%. The number holds up when nobody knows whose vial it is.
The semaglutide 10 mg arrived on day 3 with the cold pack intact and the seal unbroken. Straightforward, exactly as described.
Queried the related-substances total on lot QST-24-527; they came back with method, column and detection limit. That depth is rare.
Shipped from their warehouse in Germany, arrived day 4, documentation complete.
Sixth order from them, all BPC-157 5 mg. Sent one vial from each to PeptideMeter and the whole set landed inside half a point of each other. That flatness is exactly what I pay for.
Peptide content reported at 98.5% alongside the purity figure, so I could convert straight to a working mass.
Weighed 5 vials from the cagrilintide 5 mg order against label. Every one inside 2% of stated mass. Fill consistency is harder than purity and they have it.
The certificate for lot QST-25-402 carried method, wavelength, water content and an itemised related-substances table. Complete on the first pass.
Their warehouse in the United States carries the lines I reorder, so there is no wait on a factory run. Day 4 every time.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from qingdaosabertechnology.com. Visit QST → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Qingdao Saber Technology Pharmaceutical sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.